Aventis Pharmaceuticals Inc.

Aventisub II Inc.

George A Keesler

Zhengbin Yao

Cesare Mondadori

Clarence C Morse

Fernando Camacho

Yong Guo

The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Membrane penetrating peptides and uses thereof

The present invention is directed to methods to identify test compounds that alter circadian rhythms of mammals, and more specifically, directed to methods for determining the ability of a test compound to alter hCKI &dgr; and &egr; phosphorylation of a human Period protein. The present invention is also directed to a method for determing the ability of a test compound to selectively alter phosphorylation, interaction with, or alternatively degradation, of one or more human Period proteins relative to its ability to alter phosphorylation, interaction with, or alternatively degradation, of a different human Period protein.

Screening methods for altering circadian rhythms and for human casein kinase I &dgr; and/or &egr; phosphorylation of human clock proteins, period 1, -2 and -3

Growing community of inventors

Sommerville, NJ, United States of America

George A Keesler